Skip to main content
. Author manuscript; available in PMC: 2021 May 10.
Published in final edited form as: J Am Coll Cardiol. 2020 Mar 16;75(14):1644–1656. doi: 10.1016/j.jacc.2020.02.009

TABLE 4.

Valsartan-adjusted Change in Systolic Blood Pressure at the 4 Week Visit by Treatment Arm

Baseline Systolic Blood Pressure Group Sacubitril/Valsartan Arm (N=2379) Valsartan Arm (N=2366) Treatment Effect of Sacubitril/valsartan vs. Valsartan
4-week Change in SBP (95% CI) 4-week Change in SBP (95% CI) 4-week Change in SBP (95% CI) P-value
All Patients −1.8 (−2.4, −1.2) +3.4 (+2.8, +4.1) −5.2 (−6.0, −4.4) <0.001
SBP < 120 mmHg +5.5 (+4.4, +6.6) +10.7 (+9.5, +11.9) −5.3 (−6.9, −3.6) <0.001
120 mmHg ≤ SBP <129 mmHg +1.4 (+0.3, +2.5) +6.3 (+5.2, +7.4) −4.9 (−6.5, −3.3) <0.001
130 mmHg ≤ SBP < 139 mmHg −3.8 (−4.9, −2.7) +1.3 (+0.1, +2.4) −5.1 (−6.7, −3.5) <0.001
SBP ≥ 140 mmHg −8.5 (−9.6, −7.4) −3.1 (−4.3, −2.0) −5.4 (−7.0, −3.9) <0.001

SBP, systolic blood pressure.

Analyses adjust for baseline blood pressure.